(Q44571944)

4 December 2017

title

Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia (English)

1 reference

4 December 2017

1 reference

1 reference

Haralampos J Milionis

1

1 reference

4 December 2017

John Papakostas

2

1 reference

4 December 2017

Anna Kakafika

3

1 reference

4 December 2017

George Chasiotis

4

1 reference

4 December 2017

Konstantine Seferiadis

5

1 reference

4 December 2017

Moses S Elisaf

6

1 reference

4 December 2017

publication date

1 August 2003

1 reference

The Journal of Clinical Pharmacology

4 December 2017

published in

1 reference

4 December 2017

volume

43

1 reference

4 December 2017

issue

8

1 reference

4 December 2017

page(s)

825-830

1 reference

Homocysteine and cardiovascular disease: current evidence and future prospects

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Total homocysteine and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Plasma total homocysteine and hospitalizations for cardiovascular disease: the Hordaland Homocysteine Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Homocysteine: an emergent cardiovascular risk factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Homocysteine-lowering treatment: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Homocyst(e)ine and coronary heart disease: pharmacoeconomic support for interventions to lower hyperhomocyst(e)inaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Drugs affecting homocysteine metabolism: impact on cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Effects of fenofibrate and gemfibrozil on plasma homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Fenofibrate raises plasma homocysteine levels in the fasted and fed states

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

High-dose simvastin (80 mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesteromia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Effect of atorvastatin on serum uric acid levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Fibrate treatment can increase serum creatinine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Effects of fibrates on serum metabolic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Fenofibrate induces a selective increase of protein-bound homocysteine in rodents: a PPARalpha-mediated effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Implication of fibrate therapy for homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Homocysteine and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Hyperhomocysteinemia: an independent risk factor for vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Plasma homocysteine levels and mortality in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Serum homocysteine increases after therapy with fenofibrate or bezafibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Implication of fibrate therapy for homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Implication of fibrate therapy for homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Lipid-lowering drugs and homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Effect of smoking cessation and tobacco type on the risk of cancers of the upper aero-digestive tract in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003255920

21 January 2018

Identifiers

DOI

10.1177/0091270003255920

1 reference

4 December 2017

1 reference